RxDoctor Payments Data

Vicky Bakhos Webb

Family Medicine · Midland, TXNPI 1033597406

Payments from drug & device makers

$3,668in general payments, 2019–2025

Across 150 payments — averaging $24.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$842
  • AbbVie$748
  • Lilly USA, LLC$438
  • Revance Therapeutics, Inc.$407
  • Astellas Pharma US Inc$209
  • Boehringer Ingelheim$195
  • plus $828 from 14 others

What the payments were for

  • Food & beverage$3,47895%
  • Education$1905%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,668 in reported general payments places this provider in the 80th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$14,223
Medicare patients
37
Services billed
795

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MounjaroTirzepatide16$16,354
FarxigaDapagliflozin Propanediol13$11,707
EliquisApixaban12$8,246
Trelegy ElliptaFluticasone/Umeclidin/Vilanter11$6,734
Tresiba Flextouch U-200Insulin Degludec12$5,014
Rosuvastatin Calcium14$765
Levothyroxine Sodium40$693
Gabapentin24$659
Losartan Potassium17$355
Lisinopril25$349
Metformin Hcl27$346
Fluticasone Propionate22$342
Omeprazole13$302
Atorvastatin Calcium30$297
Tamsulosin Hcl21$284

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCMounjaro$438$16,35416 claims
AstraZenecaFarxiga$158$11,70713 claims
PfizerEliquis$55$8,24612 claims
GSKTrelegy Ellipta$97$6,73411 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 8,760 family medicine providers in Texas.

Other family medicine in Midland

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →